key: cord-0864793-rx77dvqo
authors: Ramezani, Neda; Ashtari, Fereshteh; Bastami, Elahe Abdi; Ghaderi, Kimia; Hosseini, Sayed Mohsen; Naeini, Maryam Kazemi; Rajabi, Fatemeh; Adibi, Iman
title: Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population
date: 2021-01-29
journal: Mult Scler Relat Disord
DOI: 10.1016/j.msard.2021.102798
sha: 795ed92247d51426f653562b9924a433a13fd6f0
doc_id: 864793
cord_uid: rx77dvqo

BACKGROUND: There are reports that stress-related disorders are increasing during coronavirus disease 2019 (COVID-19) pandemic. Patients with Multiple Sclerosis (MS) are at higher risk of developing psychiatric disorders, which result in worsening of their disability. There are concerns about the mental health of MS patients during this pandemic. OBJECTIVE: We aimed to evaluate the prevalence of anxiety, depression, and levels of fear about Corona in MS patients during the COVID-19 pandemic. MATERIALS AND METHODS: This was a cross-sectional study on MS patients who were admitted to the MS clinics affiliated with Isfahan University of medical sciences from May to June 2020. Anxiety and depression were evaluated according to the Hospital Anxiety and Depression Scale (HADS). The Corona Fear Questionnaire developed by Ahorsu et al. was applied to evaluate the state of fear about COVID-19. Chi-square tests were used to compare depression and anxiety between different groups, Kruskal-Wallis was used for fear scores, Spearman correlation coefficient was also reported for correlations. RESULTS: 410 MS patients with a mean age of 38.6 years (±10.35) were enrolled in the study. Among those patients who answered the HADS questionnaire completely (n=399, n=388, for anxiety and depression subscales respectively) the prevalence of anxiety and depression were 31.2% (n=128) and 39.3% (n=161), respectively. There was no significant relationship between anxiety and depression with any of the following variables: sex, marital status, history of drug abuse, smoking, duration of taking psychiatric medication, being tested for COVID-19, being quarantined. Regarding fear about COVID-19, patients with depression or anxiety showed higher scores on the fear questionnaire (p-value=0.03, p-value=0.008 respectively). CONCLUSIONS: The prevalence of anxiety and depression in MS patients was higher than previously reported. Fear about COVID-19 was correlated with anxiety and depression. Multicenter studies are required to develop specific recommendations for screening mental health problems in MS patients during COVID pandemic.

Multiple sclerosis (MS) is a chronic disease of the central nervous system and the most common cause of neurological disability in young adults among which depression and anxiety disorders are more common (Paparrigopoulos et al., 2010) . These disorders may be present even at the onset of MS and increase over the course of the disease , so that about 95% of MS patients may experience psychiatric comorbidities during their lifetime (Paparrigopoulos et al., 2010) .

Since December 2019 we are experiencing an unprecedented time, as the Coronavirus Disease 2019 (COVID-19) pandemic is causing stress and fear all over the world. There are increasing reports of stress-related disorders, including anxiety and depression, as well as alcohol and tobacco abuse (Ozamiz-Etxebarria et al., 2020). There will be more concerns about mental health of patients with chronic diseases, such as MS. They are also more vulnerable to consequences of psychiatric disorders. Psychiatric disorders (i.e. anxiety) can increase disability, relapse rate, MRI activity, and suicidal thoughts and behaviors in MS patients (Seyed Ahadi et al., 2020 , McKay et al., 2018 , Artemiadis et al., 2011 .

It is reasonable that anxiety has a negative effect on self-rated quality of life in MS patients (Chertcoff et al., 2020) . The extent to which quarantine, social distancing and pandemic related fears can influence MS patients' health should be addressed more explicitly. The aim of this study was to investigate the prevalence of anxiety, depression, and levels of fear about COVID-19, in MS patients during COVID-19 pandemic.

This was a cross-sectional study on MS patients, diagnosed by recent Mc Donald criteria (Thompson et al., 2018) , who were admitted to the MS clinic affiliated with Isfahan University of medical sciences from May to June 2020. The study was approved by the Ethics Committee of Isfahan University of Medical Sciences with the ethics code of IR.MUI. MED.REC.1399.379. Demographic information and clinical course descriptions (e.g. age, sex, age at the onset of MS, history of relapse within last one year, history of moderate to severe MS relapse (which required high dose steroid therapy)) were recorded for each patient (Table 1) .

We applied Hospital Anxiety and Depression Scale (HADS) to assess the state of anxiety and depression. The HADS questionnaire is a reliable self-assessment tool for detecting severity of anxiety and depression in outpatient clinics. It has seven items each for depression and anxiety subscales. Each item is scored on a 0 to 3 range. The total score (e.g. sum of the respective 7 items for each subscale and 14 items for overall score). A total subscale score of ≥8 points out of a possible 21 in the HADS questionnaire was considered as positive for anxiety and the same cut-off was applied for depression. The reliability and validity of the Persian version of the HDAS questionnaire were reported previously (Montazeri et al., 2003) .

The Corona Fear Questionnaire was applied to evaluate the fear about COVID-19. This tool consists seven items with a 1 to 5 scale (1= strongly disagree, 5= strongly agree). The total score is from 5 to 35, the higher the total score the more the fear of coronavirus. The validity and reliability of this scale was studied and established in different populations as well as in the Iranian population (Ahorsu et al., 2020) .

Chi-square tests were performed to compare depression and anxiety status between different groups. The global score of fear questionnaire were analyzed using Mann-Whitney and Kruskal-Wallis tests. Spearman correlation coefficient was also reported for correlations. Significant level for tests was considered at 0.05. Statistical analysis was performed with SPSS version 25.0.

Relevant demographic information for 410 participants with MS (326 females and 84 males) is summarized in Table 1 . The mean age (±SD) of the patients was 38.60 (±10.35) years. Among all participants, 45.4% (n=186) had an academic degree. Also, 75.7% of the participants (n=311) were married, and 27.3% (n=112) were employed.

More than half of the patients (56.3%, n=224) were being quarantined at home during the COVID-19 pandemic, and 9.3% of patients (n=38) were being tested for COVID-19.

Among those patients who answered the HADS questionnaire completely, the prevalence of depression was 39.3% (n=161) and 31.2% (n=128) had symptoms of anxiety. Depressive subjects were significantly older than participants without depression (40.71±10.59, 37.37±9.94, p-value=0.002). Similar results were obtained regarding the mean age of patients with symptoms of anxiety in comparison to those without these symptoms (39.93±10.18, 37.75±10.28, p-value=0.034).

Patients with symptoms of depression and anxiety were without academic degree in comparison to those without these symptoms (50.2% vs 31.1%, p-value<0.001, 40.6% vs 22.0%, p-value<0.001 respectively). The history of COVID-19 in family (positive / suspicious cases), was reported more frequently by patients with depression (69.2% vs 30.8%, p-value=0.047) in comparison to those without these symptoms. The mean age at the onset of MS was higher in patients with symptoms of anxiety in comparison to those without these symptoms (30.80±10.26 vs 28.35±8.83, p-value=0.025; table 4). State of depression and anxiety in MS patients under different treatment are summarized in Table 2 .

There was no significant relationship between either anxiety or depression with any of the following variables: sex, marital status, history of drug abuse, smoking, duration of taking psychiatric medication, being tested for COVID-19, being quarantined.

Regarding fear about COVID-19, patients with depression or anxiety showed higher scores on the fear questionnaire, in comparison to those without depression or anxiety ( 

In this cross-sectional study, we examined prevalence of anxiety, depression, and levels of fear about COVID-19 in patients with MS during the COVID-19 pandemic. Our results showed that, during the COVID-19 pandemic, the prevalence of anxiety and depression was (31.2%) and (39.3%), respectively in our MS patients. Previous studies have reported 22.1% for anxiety and 30.5% for depression (Boeschoten et al., 2017) . Anxiety in MS patients is associated with lower self-efficacy, higher levels of disability, and stress (Ahmadi et al., 2018) . Mental health issues are of great concern during the current COVID-19 pandemic, as psychological distress and anxiety were increasingly reported even in the healthy general population (Serafini et al., 2020 , Wang et al., 2020 . MS patients are more vulnerable to develop depression and anxiety disorders in comparison to healthy populations (Beiske et al., 2008) and need more attention as mental health issues can deteriorate their physical disability as well . Our results showed that fear about COVID-19 correlates with state of anxiety as well as of depression. Accordingly, MS patients should be well informed about effective coping strategies such as fostering self-efficacy as well as maintaining a healthy lifestyle and social contacts to avoid anxious and depressive symptoms. These coping strategies can consequently avoid new progression or worsening of the disease.

The present study showed that MS patients with academic degree, have experienced less anxiety during the COVID-19 pandemic. This was similar to the findings of another study on factors associated with anxiety in MS patients before the COVID-19 pandemic (Pham et al., 2018 , Tsivgoulis et al., 2007 . Persons without academic degree may be less likely to gather required information such as relevant protocols for self-protections, clinicians should pay more attention to these patients and inform them more precisely about how and where to receive medical help or social support if needed. This may provide patients with more confidence and less anxiety.

According to our results, patients with a history of psychiatric disorder were more prone to depression during the COVID-19 pandemic, 58.6% of these patients had depression (Table 3) . Pre-existing mental disorders are generally associated with higher risk of anxiety and depression in MS patients (Chertcoff et al., 2020) . These patients require more support regarding coping with fear about COVID-19. The same recommendation is reasonable for patients with older age who were also according to our results, more susceptible to anxiety during the COVID-19 pandemic. They have also reported significantly higher depression scores than younger participants. In a previous study conducted on 7,786 MS patients; the lowest levels of depression were found in the youngest group of patients and the highest in the patients aged between 45-64 years old; however, people with older age had less risk for experiencing anxiety (Jones et al., 2012) .The different results in our study can be due to higher death rate in people with older ages during COVID-19 pandemic, leading to high levels of anxiety in older MS patients. Moreover, we suppose that the age at the onset of MS seems to be more predictive than the current age of patients regarding developing anxiety. The patients who were diagnosed with MS at older ages have experienced more anxiety during the current pandemic in comparison to those with younger ages at the disease onset.

History of MS relapse within last one year and recent treatment with corticosteroids indicating a recent disease activity, were associated with fear about COVID-19 (Which was not statistically significant (. It is reasonable to recommend a close follow up of patients with active Although our center is the only comprehensive center for MS in the province, data gathered from single-center studies has limited external validity and should be confirmed with future studies. At the beginning of the study (May 2020) there were 2577913 confirmed cases and 121696 deaths, which had 32.09% decrease amount of deaths compared to April. Also, at the end of the study (June 2020) confirmed cases and deaths were 5188670 and158533 (Organization WH 2020) . Obviously, these numbers vary country to country. This changing of the epidemiologic pattern of the COVID-19 pandemic over the time, may alter the patient's behaviour and reaction as well.

This study showed that MS patients, especially those with a history of psychiatric comorbidities, recent disease activity, and patients without academic degree are more prone to psychiatric disorders during the COVID-19 pandemic. Data from multi-center studies are needed to achieve better recommendations regarding screening psychiatric problems and supportive strategies in clinical practice.

Compliance with ethical guidelines Written informed consent was obtained from all participants and the research protocol was approved by the medical ethics committee of Isfahan University of Medical Sciences. Note: unless otherwise indicated, data are number of patients, and data in parenthesis are percentages. P-values are for comparison of frequency of depression between groups. * Mean (standard deviation) ** Positive / suspicious cases Note: unless otherwise indicated, data are number of patients, and data in parenthesis are percentages. P-values are for comparison of frequency of anxiety between groups. * Mean (standard deviation) ** Positive / Suspicious cases

The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. International review of psychiatry

The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review

Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain

Psychiatric Advice During COVID-19 Pandemic for Patients with Multiple Sclerosis

Psychiatric comorbidity is associated with disability progression in multiple sclerosis

Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review

Anxiety in Argentinian patients with multiple sclerosis: Prevalence and associated factors. Multiple sclerosis and related disorders 41

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health and quality of life outcomes 1

The Fear of COVID-19 Scale: Development and Initial Validation

Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis

Relationship Between Anxiety and Depression with Disability Over Multiple Sclerosis Patients in Rafsanjan

The psychological impact of COVID-19 on the mental health in the general population

Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China

Depression and anxiety amongst multiple sclerosis patients

Effect of comorbidity on mortality in multiple sclerosis

The prevalence of anxiety and associated factors in persons with multiple sclerosis

Associations of the Expanded Disability Status Scale with anxiety and depression in multiple sclerosis outpatients

A large-scale study of anxiety and depression in people with Multiple Sclerosis: a survey via the web portal of the UK MS Register

Coronavirus disease (COVID-19) outbreak. 2020

Conduction of the present research was made possible through the supports received from Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences (approved No. 199141), Isfahan, Iran. We are grateful to all the patients who helped us in our project.

All authors contributed in preparing this article. 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Institutional financial support was provided by Isfahan University of Medical Sciences for this study.